(Q39195699)

9 September 2017

title

Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension (English)

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

24 October 2022

main subject

arterial hypertension

0 references

author name string

G. Frithz

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A26519

24 October 2022

language of work or name

English

0 references

publication date

1 January 1978

1 reference

full work available at URL

9 September 2017

http://www.tandfonline.com/doi/pdf/10.1185/03007997809111902

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

Current Medical Research and Opinion

24 October 2022

published in

1 reference

9 September 2017

volume

5

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

383-387

1 reference

Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases

9 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

The dropout problem in antihypertensive treatment. A pilot study of social and emotional factors influencing a patient's ability to follow antihypertensive treatment

24 October 2022

2

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

Propranolol in hypertension: a dose-response study

24 October 2022

3

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

Pharmacology of nadolol (SQ 11725), a β-adrenergic antagonist lacking direct myocardial depression

24 October 2022

4

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

Treatment of Hypertension with Propranolol

24 October 2022

5

1 reference

https://api.crossref.org/works/10.1185/03007997809111902

24 October 2022

Identifiers

1 reference

9 September 2017

1 reference